These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 18203702)

  • 21. Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Kuhn H
    Z Kardiol; 2004 Jun; 93(6):493-9. PubMed ID: 15252744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac electromechanical mapping in analyzing the mechanism of left ventricular remodeling immediately after percutaneous transluminal septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Chen SL; Huang J; Ye F; Shan SJ; Zhang JJ; Duan BX; Chen YD
    Chin Med J (Engl); 2005 Nov; 118(21):1779-85. PubMed ID: 16336814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Percutaneous transluminal septal myocardial ablation in patients with obstructive septal hypertrophic myocardiopathy. Acute results and 3-year follow-up].
    Llamas-Esperón GA; Loera Pinales A; Sandoval Navarrete S; Zamora Muciño A; Ramírez Robledo MA; Varela Ortiz S; Casas Juárez U; Fuantos Delgado Mde L; Albarrán Domínguez J; Muñoz Sandoval R; Sandoval Rodríguez E; Ruiz Esparza ME
    Arch Cardiol Mex; 2009; 79(1):33-40. PubMed ID: 19545072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of surgical myectomy after unsuccessful alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy.
    Nagueh SF; Buergler JM; Quinones MA; Spencer WH; Lawrie GM
    J Am Coll Cardiol; 2007 Aug; 50(8):795-8. PubMed ID: 17707185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome.
    Veselka J; Procházková S; Duchonová R; Bolomová-Homolová I; Pálenícková J; Tesar D; Cervinka P; Honek T
    Catheter Cardiovasc Interv; 2004 Oct; 63(2):231-5. PubMed ID: 15390343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Lieder F; Bartelsmeier M; Leuner C; Borchert B; Meyer zu Vilsendorf D; Strunk-Mueller C; Reinhardt J; Feuchtl A; Stellbrink C; Kuhn H
    J Am Coll Cardiol; 2007 Jun; 49(24):2356-63. PubMed ID: 17572252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience.
    Asil S; Kaya B; Canpolat U; Yorgun H; Şahiner L; Çöteli C; Arat A; Aytemir K
    Catheter Cardiovasc Interv; 2018 Sep; 92(3):557-565. PubMed ID: 29205803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Alcohol concentration in the coronary sinus after transarterial ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy].
    Klein N; Mende M; Hagendorff A; Neugebauer A; Pfeiffer D
    Dtsch Med Wochenschr; 2000 May; 125(19):579-83. PubMed ID: 11320715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Sorajja P; Valeti U; Nishimura RA; Ommen SR; Rihal CS; Gersh BJ; Hodge DO; Schaff HV; Holmes DR
    Circulation; 2008 Jul; 118(2):131-9. PubMed ID: 18591440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Percutaneous transluminal septal myocardial ablation: a novel, nonsurgical treatment for symptomatic hypertrophic cardiomyopathy.
    Kar S; Makkar R
    Rev Cardiovasc Med; 2001; 2(2):97-102. PubMed ID: 12439386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
    Seggewiss H; Faber L; Gleichmann U
    Thorac Cardiovasc Surg; 1999 Apr; 47(2):94-100. PubMed ID: 10363608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear magnetic resonance for the assessment of the effects of alcohol septal ablation in hypertrophic cardiomyopathy.
    Kornacewicz-Jach Z; Wojtarowicz A; Goos H; Schulz-Menger J; Goracy J; Płońska E; Przybycień K
    Kardiol Pol; 2004 Nov; 61(11):461-7. PubMed ID: 15883594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and safety of transthoracic echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation for the treatment of patients with obstructive hypertrophic cardiomyopathy].
    Liu LW; Zuo L; Zhou MY; Li J; Zhou XD; He GB; Zhang J; Zhang JZ; Liu B; Yang J; Xu B
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Apr; 47(4):284-290. PubMed ID: 31060187
    [No Abstract]   [Full Text] [Related]  

  • 34. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
    Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S
    J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy.
    Chang SM; Lakkis NM; Franklin J; Spencer WH; Nagueh SF
    Circulation; 2004 Feb; 109(7):824-7. PubMed ID: 14967729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction.
    Seggewiss H; Faber L
    Eur J Echocardiogr; 2000 Dec; 1(4):277-80. PubMed ID: 11916606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a review of the literature.
    Veselka J
    Med Sci Monit; 2007 Apr; 13(4):RA62-8. PubMed ID: 17392660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Obergassel L; Lieder F; Leuner C; Strunk-Mueller C; Meyer Zu Vilsendorf D; Beer G; Kuhn H
    Pacing Clin Electrophysiol; 2005 Apr; 28(4):295-300. PubMed ID: 15826262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients.
    Lawrenz T; Borchert B; Leuner C; Bartelsmeier M; Reinhardt J; Strunk-Mueller C; Meyer Zu Vilsendorf D; Schloesser M; Beer G; Lieder F; Stellbrink C; Kuhn H
    J Am Coll Cardiol; 2011 Feb; 57(5):572-6. PubMed ID: 21272748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous transluminal catheter-based coil embolization of septal artery as a treatment for hypetrophic obstructive cardiomyopathy.
    Vaishnav S; Gautam N
    Indian Heart J; 2007; 59(2):195-6. PubMed ID: 19122258
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.